[go: up one dir, main page]

DE69814049D1 - Substituierte benzimidazole als nicht-nucleoside reverse transcriptase inhibitore - Google Patents

Substituierte benzimidazole als nicht-nucleoside reverse transcriptase inhibitore

Info

Publication number
DE69814049D1
DE69814049D1 DE69814049T DE69814049T DE69814049D1 DE 69814049 D1 DE69814049 D1 DE 69814049D1 DE 69814049 T DE69814049 T DE 69814049T DE 69814049 T DE69814049 T DE 69814049T DE 69814049 D1 DE69814049 D1 DE 69814049D1
Authority
DE
Germany
Prior art keywords
reverse transcriptase
substituted benzimidazoles
transcriptase inhibitors
nucleoside reverse
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69814049T
Other languages
English (en)
Other versions
DE69814049T2 (de
Inventor
J Michejda
Marshall Morningstar
Thomas Roth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institutes of Health NIH
Original Assignee
National Institutes of Health NIH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Institutes of Health NIH filed Critical National Institutes of Health NIH
Publication of DE69814049D1 publication Critical patent/DE69814049D1/de
Application granted granted Critical
Publication of DE69814049T2 publication Critical patent/DE69814049T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE69814049T 1997-02-25 1998-02-24 Substituierte benzimidazole als nicht-nucleoside reverse transcriptase inhibitore Expired - Fee Related DE69814049T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3850997P 1997-02-25 1997-02-25
US38509P 1997-02-25
PCT/US1998/003588 WO1998037072A1 (en) 1997-02-25 1998-02-24 Substituted benzimidazoles as non-nucleoside inhibitors of reverse transcriptase

Publications (2)

Publication Number Publication Date
DE69814049D1 true DE69814049D1 (de) 2003-06-05
DE69814049T2 DE69814049T2 (de) 2004-02-19

Family

ID=21900368

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69814049T Expired - Fee Related DE69814049T2 (de) 1997-02-25 1998-02-24 Substituierte benzimidazole als nicht-nucleoside reverse transcriptase inhibitore

Country Status (8)

Country Link
US (2) US6369235B1 (de)
EP (1) EP0963371B1 (de)
JP (1) JP2001513084A (de)
AT (1) ATE238998T1 (de)
AU (1) AU741772B2 (de)
CA (1) CA2281927C (de)
DE (1) DE69814049T2 (de)
WO (1) WO1998037072A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60034578D1 (de) * 1999-08-26 2007-06-06 Us Health Substituierte benzimidazole als nicht-nucleosid-inhibitoren von reverser transcriptase
US6770666B2 (en) 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
CN1623984A (zh) 1999-12-27 2005-06-08 日本烟草产业株式会社 稠环化合物及其药物用途
US6242461B1 (en) * 2000-01-25 2001-06-05 Pfizer Inc. Use of aryl substituted azabenzimidazoles in the treatment of HIV and AIDS related diseases
GB0005366D0 (en) * 2000-03-06 2000-04-26 Xenova Ltd Pharmaceutical compounds
AU2002211662A1 (en) * 2000-10-12 2002-04-22 Smith Kline Beecham Corporation Nf-kappab inhibitors
US7030150B2 (en) 2001-05-11 2006-04-18 Trimeris, Inc. Benzimidazole compounds and antiviral uses thereof
JP4730574B2 (ja) * 2001-05-18 2011-07-20 山田化学工業株式会社 ベンズイミダゾール化合物、アゾベンズイミダゾール化合物とそのキレート化合物
EP1516873A1 (de) * 2003-09-22 2005-03-23 Facultés Universitaires Notre-Dame de la Paix 2-Pyridinon-Derivate als HIV Inhibitoren
CA2612419C (en) * 2005-06-23 2017-06-13 Array Biopharma Inc. Process for preparing benzimidazole compounds
PE20080888A1 (es) 2006-10-18 2008-08-26 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE LA ACIL-TRANSFERASA DE ACIL-CoA-DIACIL-GLICEROL 1 (DGAT1)
TW200831085A (en) * 2006-12-13 2008-08-01 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors
US20080173808A1 (en) * 2007-01-18 2008-07-24 Schering Corporation Process and device for response normalized liquid chromatography nanospray ionization mass spectrometry (rnlc-nsi-ms)
DE102007008420A1 (de) * 2007-02-21 2008-08-28 Merck Patent Gmbh Benzimidazolderivate
US20080249305A1 (en) * 2007-03-27 2008-10-09 Calderwood David J Novel imidazole based heterocycles
CA2681739A1 (en) * 2007-03-27 2008-10-02 Abbott Laboratories Novel imidazo based heterocycles
WO2008153701A1 (en) * 2007-05-24 2008-12-18 Schering Corporation Compounds for inhibiting ksp kinesin activity
US8940730B2 (en) 2007-09-18 2015-01-27 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions of treating a Flaviviridae family viral infection
US9149463B2 (en) * 2007-09-18 2015-10-06 The Board Of Trustees Of The Leland Standford Junior University Methods and compositions of treating a Flaviviridae family viral infection
EP2203168B1 (de) * 2007-09-18 2014-07-16 Stanford University Zusammensetzungen zur Behandlung einer Infektion mit einem Virus der Flaviviridae-Familie
US9101628B2 (en) * 2007-09-18 2015-08-11 The Board Of Trustees Of The Leland Stanford Junior University Methods and composition of treating a flaviviridae family viral infection
WO2010107739A2 (en) 2009-03-18 2010-09-23 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions of treating a flaviviridae family viral infection
BR112014030940B1 (pt) * 2012-06-11 2022-09-06 UCB Biopharma SRL Benzimidazóis que modulam tnf-alfa e composição farmacêutica compreendendo os mesmos
KR102696304B1 (ko) 2015-03-18 2024-08-16 브리스톨-마이어스 스큅 컴퍼니 Tnf의 억제제로서 유용한 헤테로시클릭 화합물
MX2017011434A (es) 2015-03-18 2018-01-25 Squibb Bristol Myers Co Compuestos heterociclicos triciclicos sustituidos.
KR102630010B1 (ko) 2015-03-18 2024-01-25 브리스톨-마이어스 스큅 컴퍼니 Tnf의 억제제로서 유용한 트리시클릭 헤테로시클릭 화합물
ES2828696T3 (es) 2015-08-03 2021-05-27 Bristol Myers Squibb Co Compuestos cíclicos útiles como moduladores de TNF alfa

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2096648B1 (de) * 1970-04-17 1973-08-10 Gen Electric
FR2092648A1 (en) * 1970-06-04 1972-01-28 Fuveau Sa 2-(fluorophenyl) benzimidazoles - as antiinflammatory and analgesic agents
US3825537A (en) 1972-02-28 1974-07-23 Squibb & Sons Inc 1-thiazolin-2-yl(or thiazin-2-yl)-2-aminobenzimidazoles and derivatives thereof
US4214089A (en) 1978-07-18 1980-07-22 American Home Products Corporation Thiazolo[3,2-a]benzimidazoles, imidazo [2,1-b]thiazoles, and related compounds as antineoplastic agents, and enhancers of the immune response
US4434288A (en) 1982-04-08 1984-02-28 Eli Lilly And Company Preparation of substituted 1-thiazinyl or 1-thiazolyl-2-aminobenzimidazoles
US5356917A (en) 1985-08-09 1994-10-18 Eli Lilly And Company Aryl-substituted rhodanine derivatives
FR2587029B1 (fr) 1985-09-11 1987-10-30 Synthelabo Derives de benzimidazole, leur preparation et leur application en therapeutique
IT1243362B (it) * 1990-07-25 1994-06-10 Pietro Monforte Sintesi di attivita' anti-hiv di 1h, 3h-tiazolo 3,4-a benzimidazoli 1-sostituiti
US5248672A (en) 1990-11-01 1993-09-28 The Regents Of The University Of Michigan Polysubstituted benzimidazole nucleosides as antiviral agents
GB9205368D0 (en) 1992-03-12 1992-04-22 Pfizer Ltd Benzimidozole anthelmintic agents
US5622960A (en) 1992-04-14 1997-04-22 The United States Of America As Represented By The Department Of Health And Human Services Topoisomerase II inhibitors and therapeutic uses therefor
WO1995008540A1 (en) 1993-09-22 1995-03-30 The Wellcome Foundation Limited Bis(amidinobenzimidazolyl)alkanes as antiviral agents
US6815461B1 (en) 1994-01-20 2004-11-09 The University Of North Carolina At Chapel Hill Method of inhibiting retroviral integrase
US5545653A (en) 1995-06-07 1996-08-13 Eli Lilly And Company Anti-viral compounds
GB9600143D0 (en) 1996-01-05 1996-03-06 Wellcome Found Therapeutic compounds
US5821242A (en) 1996-06-06 1998-10-13 Eli Lilly And Company Anti-viral compounds
WO1998055120A1 (en) 1997-06-04 1998-12-10 Eli Lilly And Company Anti-viral compounds

Also Published As

Publication number Publication date
EP0963371A1 (de) 1999-12-15
US20030191160A1 (en) 2003-10-09
ATE238998T1 (de) 2003-05-15
AU741772B2 (en) 2001-12-06
US6369235B1 (en) 2002-04-09
DE69814049T2 (de) 2004-02-19
US6894068B2 (en) 2005-05-17
EP0963371B1 (de) 2003-05-02
CA2281927C (en) 2004-01-27
CA2281927A1 (en) 1998-08-27
WO1998037072A1 (en) 1998-08-27
JP2001513084A (ja) 2001-08-28
AU6337198A (en) 1998-09-09

Similar Documents

Publication Publication Date Title
ATE238998T1 (de) Substituierte benzimidazole als nicht-nucleoside reverse transcriptase inhibitore
DE69823344D1 (de) Substituierte benzimidazol-derivaten und ihre verwendung zur behandlung retroviraler infektionen
MY142948A (en) Benzophenones as inhibitors of reverse transcriptase
EA199700222A1 (ru) Сульфонилалканоиламиногидроксиэтиламиносульфонамид в качестве ингибиторов ретровирусной протеазы
MX9706913A (es) Compuestos de bis-aminacido-hidroxietilamina-sulfonamida inhibidoresde proteasan retroviral, composiciones que los contienen y ek uso de los mismos.
LV12719A (lv) Benzoxazinones as inhibitors of hiv reverse transcriptase
PT824524E (pt) Compostos de pirimidina-tioalquilo e alquileter substituidos em alfa como inibidores da transcriptase reversa viral
ATE229033T1 (de) Heterocyclocarbonyl-aminosäure-hydroxyethylamin - sulfonamid inhibitoren retroviraler proteasen
DE69928779D1 (de) Nichtnukleoside reverse transkriptase-hemmer zur behandlung von hiv-infektion
ES2123156T3 (es) Compuestos y procedimientos de inhibicion de hiv y virus semejantes.
ZA991029B (en) Composition and methods for treatment of hiv infections.
ES2132383T3 (es) Inhibidores de proteasa hiv.
BR0314657A (pt) Inibidores de fusão de derivados de peptìdeo de infecção de hiv
ATE213231T1 (de) Michellamine zur verwendung als antivirale wirkstoffe, zusammensetzung und behandlungsverfahren
TR200302134T4 (tr) 2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı.
WO2003100036A3 (fr) Sulfolipides antiretroviraux extraits de spirulines, leur procede d'obtention, les compositions les contenant et leur utilisation comme inhibiteurs de la transcriptase inverse des virus vih.
DE60227665D1 (de) Tsg101 als inhibitor der hiv-produktion
SE9402241D0 (sv) Inhibitor
NO951608L (no) Anvendelse av BHAP-forbindelser i kombinasjon med andre ikke-nukleoside reverstranskriptaseinhibitorer for behandling av HIV-infeksjon
ATE412423T1 (de) Peroxiredoxin-arzneistoffe zur behandlung einer hiv-1-infektion
ATE360621T1 (de) Substituierte benzimidazole als nicht-nucleosid- inhibitoren von reverser transcriptase
ES2195905T3 (es) Compuestos de tiofen-etil-tiourea y su uso en el tratamiento de sida.
NO20024522L (no) Sammensetninger med anti-hiv-aktivitet
TR200401036T1 (tr) Yüksek kan basıncının tedavisi için citalopram.
UA31078A (uk) Інгібітор вірусу імунодефіциту людини ( даримід )

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee